Evidence map›Paper›PMID 39684612›Full record

ArticleInternational journal of molecular sciences2024

Chemical Characterization and Assessment of the Neuroprotective Potential of

Antonis Ververis, Sotiris Kyriakou, Hariklia Paraskeva, Mihalis I Panayiotidis, Michael Plioukas, Kyproula Christodoulou

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Evaluating the Chemical Composition and Antitumor Activity ofInternational journal of molecular sciences · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Antonis VerverisNeurogenetics Department, The Cyprus Institute of Neurology and Genetics, Nicosia 2371, Cyprus.ORCID 0000-0002-6419-0566
Sotiris KyriakouDepartment of Cancer Genetics, Therapeutics and Ultrastructural Pathology, The Cyprus Institute of Neurology and Genetics, Nicosia 2371, Cyprus.ORCID 0000-0002-6195-6570
Hariklia ParaskevaNeurogenetics Department, The Cyprus Institute of Neurology and Genetics, Nicosia 2371, Cyprus.
Mihalis I PanayiotidisDepartment of Cancer Genetics, Therapeutics and Ultrastructural Pathology, The Cyprus Institute of Neurology and Genetics, Nicosia 2371, Cyprus.ORCID 0000-0002-1450-3552
Michael PlioukasDepartment of Life and Health Sciences, School of Sciences and Engineering, University of Nicosia, Nicosia 2417, Cyprus.ORCID 0000-0003-4812-4048
Kyproula ChristodoulouNeurogenetics Department, The Cyprus Institute of Neurology and Genetics, Nicosia 2371, Cyprus.ORCID 0000-0002-0622-7594

Funding

The Cyprus Institute of Neurology and Genetics N/A
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Amyloid beta-PeptidesAntioxidantsNeuroprotective AgentsPlant ExtractsAlzheimer DiseaseCell Line, TumorCell SurvivalCholinesterase InhibitorsHumansPlants, MedicinalAmyloid beta-PeptidesAntioxidantsCholinesterase InhibitorsNeuroprotective AgentsPlant ExtractsamyloidEuphrasiaextractseyebrightneuroprotection

Identifiers

PMID39684612
PMCPMC11641456

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.